<DOC>
	<DOCNO>NCT02017717</DOCNO>
	<brief_summary>The purpose study compare efficacy safety nivolumab administer alone versus bevacizumab patient diagnose recurrent glioblastoma ( type brain cancer , also know GBM ) , evaluate safety tolerability nivolumab administer alone combination ipilimumab patient different line GBM therapy .</brief_summary>
	<brief_title>A Study Effectiveness Safety Nivolumab Compared Bevacizumab Nivolumab With Without Ipilimumab Glioblastoma Patients</brief_title>
	<detailed_description>Allocation : Randomized ( Cohort 1 2 ) , Non-Randomized ( Cohorts 1b , 1c 1d )</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Subjects histologically confirm Grade IV malignant glioma Previous treatment radiotherapy temozolomide ( Cohorts 1 , 1b 2 ) First recurrence GBM ( Cohorts 1 , 1b 2 ) First diagnosis GBM resectable disease ( Cohorts 1c Part A ) First diagnosis unmethylated MGMT GBM ( Cohort 1d Cohort 1c Part B ) Karnofsky performance score 70 high More 1 recurrence GBM ( Cohorts 1 , 1b 2 ) Any recurrence GBM ( Cohorts 1c 1d ) Presence extracranial metastatic leptomeningeal disease Active , know suspected autoimmune disease Clinically significant cardiovascular disease Prior bevacizumab Vascular Endothelial Growth Factor ( VEGF ) antiangiogenic treatment ( Cohort 2 )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>